We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF

MedXY Editorial Team•Jun 9, 2026•Cardiology
alternative splicingHFpEFSRPK3TPM1

Highlights

Alternative splicing of TPM1 appears to be a previously underrecognized myofilament mechanism contributing to impaired relaxation and increased stiffness in heart failure with preserved ejection fraction (HFpEF).

The study identifies a specific pathogenic isoform shift toward TPM1b, generated by skipping exon 9a, in both human HFpEF samples and mouse models.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant PhenotypesThe PORTHOS study reveals a 16.5% prevalence of heart failure among Portuguese adults aged 50+, with HFpEF constituting over 90% of cases, mostly undiagnosed, highlighting the need for enhanced screening strategies in aging populations.Sep 15, 2026Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction ModelThe LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.Sep 11, 2026Unveiling the Role of Myeloid Cells in Right Ventricular Dysfunction in HFpEF via Sterile InflammationThis article explores how myeloid cell expansion drives right ventricular dysfunction in HFpEF through sterile inflammation, highlighting translational insights from murine models and human studies.Aug 22, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Unmasking Silent Heart Failure in Diabetes: Insights from the TARTAN-HF Trial
The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c
Aug 21, 2026
Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF TrialThe RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.Aug 15, 2026
Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical ChallengesThis article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.Aug 12, 2026